CYAN: AI 评分 40/100 — AI 分析 (4月 2026)

Cyanotech Corporation cultivates, produces, and sells natural products derived from microalgae, including BioAstin Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica. The company distributes its products through various channels, targeting the health foods, nutraceuticals, and dietary supplement markets.

Key Facts: AI Score: 40/100 Sector: Consumer Defensive

公司概况

概要：

Cyanotech Corporation, founded in 1983, specializes in microalgae-derived products like BioAstin and Spirulina, catering to the health and wellness market. With a focus on dietary supplements, the company distributes through diverse channels, including online, retail, and bulk sales, positioning itself within the competitive packaged foods sector.

CYAN是做什么的？

Cyanotech Corporation, established in 1983 and headquartered in Kailua-Kona, Hawaii, focuses on the cultivation, production, and sale of natural products derived from microalgae. The company's flagship products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant known for enhancing skin health and supporting eye, joint, and immune function. This product is marketed as a human dietary supplement and dietary ingredient. Another key product is Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement, promoted for its energy-boosting, immune-strengthening, and cardiovascular benefits, as well as its antioxidant carotenoid content. Cyanotech distributes its products through a variety of channels, including distributors, retailers, and online platforms, directly targeting consumers. Additionally, the company engages in bulk sales to manufacturers, formulators, and distributors within the health foods, nutraceuticals, and dietary supplement industries. The company also provides contract extraction services. Cyanotech's commitment to producing high-quality, microalgae-based products has allowed it to establish a presence in the competitive health and wellness market.

CYAN的投资论点是什么？

Cyanotech Corporation presents a unique investment proposition within the consumer defensive sector, specifically in the niche market of microalgae-derived health supplements. The company's focus on BioAstin and Spirulina products caters to the growing demand for natural antioxidants and dietary supplements. However, with a negative P/E ratio of -1.35 and a negative profit margin of -7.1%, the company's current profitability is a concern. The gross margin of 32.1% indicates potential for improvement in operational efficiency. Key growth catalysts include expanding distribution channels and increasing consumer awareness of the health benefits of astaxanthin and spirulina. The company's low beta of -0.21 suggests relatively low volatility compared to the market, but investors should carefully consider the risks associated with OTC-traded companies.

CYAN在哪个行业运营？

Cyanotech Corporation operates within the consumer defensive sector, specifically in the packaged foods industry, focusing on dietary supplements. The global dietary supplements market is experiencing steady growth, driven by increasing health awareness and an aging population. Key trends include the rising demand for natural and organic products, as well as the growing popularity of online retail channels. Cyanotech faces competition from other players in the nutraceuticals market. Competitors include companies that offer similar algae-based products and broader dietary supplement brands. The company's success depends on its ability to differentiate its products through quality, branding, and effective marketing.

Packaged Foods

Consumer Defensive

CYAN有哪些增长机遇？

Expansion of Online Sales Channels: Cyanotech can capitalize on the growing e-commerce trend by expanding its online sales channels. The global e-commerce market is projected to reach trillions of dollars by 2026. By investing in its online presence, improving its website user experience, and leveraging digital marketing strategies, Cyanotech can reach a broader customer base and increase sales. This includes direct-to-consumer sales and partnerships with online retailers. Timeline: Ongoing.
Strategic Partnerships and Distribution Agreements: Forming strategic partnerships with major retailers and distributors can significantly expand Cyanotech's market reach. Collaborating with established players in the health and wellness industry can provide access to new markets and customer segments. This includes partnerships with grocery chains, pharmacies, and specialty health stores. Timeline: Ongoing.
Product Innovation and New Product Development: Investing in research and development to create new and innovative products can drive growth. This includes exploring new applications for astaxanthin and spirulina, as well as developing new formulations and delivery methods. The market for innovative dietary supplements is constantly evolving, and Cyanotech can stay ahead of the curve by introducing novel products that meet consumer needs. Timeline: Ongoing.
International Market Expansion: Expanding into international markets represents a significant growth opportunity for Cyanotech. The global dietary supplements market is growing rapidly, particularly in emerging economies. By targeting specific regions with tailored marketing strategies and distribution networks, Cyanotech can tap into new sources of revenue and diversify its customer base. Timeline: Ongoing.
Increased Consumer Awareness and Education: Investing in consumer education and awareness campaigns can drive demand for Cyanotech's products. Many consumers are not fully aware of the health benefits of astaxanthin and spirulina. By educating consumers about the science behind these ingredients and their potential health benefits, Cyanotech can increase demand and build brand loyalty. This includes content marketing, social media engagement, and partnerships with health influencers. Timeline: Ongoing.

Gross Margin of 32.1% indicates potential for profitability improvements through operational efficiencies.
Negative Profit Margin of -7.1% signals challenges in achieving sustainable profitability.
Market Cap of $0.00B reflects the company's small size and potential for growth or volatility.
P/E Ratio of -1.35 indicates the company is currently not profitable, requiring further investigation into its earnings potential.
Beta of -0.21 suggests the stock is less volatile than the market, potentially offering stability in turbulent times.

CYAN提供哪些产品和服务？

Cultivates and produces microalgae.
Extracts and processes astaxanthin from microalgae.
Manufactures and packages dietary supplements.
Sells BioAstin Hawaiian Astaxanthin for skin, eye, joint, and immune health.
Sells Hawaiian Spirulina Pacifica for energy, immune support, and cardiovascular benefits.
Provides contract extraction services.

CYAN如何赚钱？

Cultivation and production of microalgae-derived products.
Direct-to-consumer sales through online channels.
Sales through distributors and retailers.
Bulk sales to manufacturers and formulators.

Health-conscious consumers seeking natural supplements.
Individuals looking for antioxidant and immune support.
Manufacturers and formulators in the health foods and nutraceuticals industries.
Retailers and distributors in the dietary supplement market.

Proprietary cultivation and extraction processes.
Established brand recognition for BioAstin and Spirulina.
Location in Hawaii provides a unique selling proposition (USP).
Long-standing relationships with distributors and retailers.

什么因素可能推动CYAN股价上涨？

Ongoing: Expansion of online sales channels to reach a broader customer base.
Ongoing: Strategic partnerships with retailers and distributors to increase market reach.
Ongoing: Product innovation and development of new formulations.
Ongoing: International market expansion to tap into new sources of revenue.
Ongoing: Increased consumer awareness and education campaigns to drive demand.

CYAN的主要风险是什么？

Potential: Increased competition from larger nutraceutical companies.
Potential: Changes in regulatory requirements for dietary supplements.
Potential: Fluctuations in raw material prices.
Potential: Negative publicity regarding the safety or efficacy of astaxanthin or spirulina.
Ongoing: Negative profit margin and limited financial resources.

CYAN的核心优势是什么？

Established brand recognition for BioAstin and Spirulina.
Proprietary cultivation and extraction processes.
Direct-to-consumer sales channel.
Unique Hawaiian origin provides a marketing advantage.

CYAN的劣势是什么？

Negative profit margin.
Limited financial resources compared to larger competitors.
Reliance on a small number of key products.
Vulnerability to fluctuations in raw material costs.

CYAN有哪些机遇？

Expansion into new international markets.
Development of new products and formulations.
Increased consumer awareness of the health benefits of astaxanthin and spirulina.
Strategic partnerships with major retailers and distributors.

CYAN面临哪些威胁？

Increased competition from larger nutraceutical companies.
Changes in regulatory requirements for dietary supplements.
Fluctuations in raw material prices.
Negative publicity regarding the safety or efficacy of astaxanthin or spirulina.

CYAN的竞争对手是谁？

Apeiron Capital Investment Corp. — Focuses on broader investment strategies. — (APRU)
Aspen Group Inc. — Operates in the education sector. — (ASPU)
Koninklijke DSM NV — Diversified nutrition, health, and sustainable living company. — (BABYF)
CMG Holdings Group Inc. — Focuses on the hospitality and entertainment industries. — (CMGHF)
Horseraceing Integrity and Safety Authority — Focuses on horseracing integrity and safety. — (HRSR)

Key Metrics

MoonshotScore: 40/100

Company Profile

CEO: Matthew Keith Custer
Headquarters: Kailua-Kona, US
Employees: 77
Founded: 1991

AI Insight

AI analysis pending for CYAN

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Cyanotech Corporation do?

Cyanotech Corporation cultivates, produces, and sells natural products derived from microalgae, primarily BioAstin Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica. BioAstin is marketed as a dietary antioxidant to enhance skin, eye, joint, and immune health, while Spirulina Pacifica is promoted as a nutrient-rich supplement for energy, immune support, and cardiovascular benefits. The company distributes these products through various channels, including direct-to-consumer online sales, retailers, distributors, and bulk sales to manufacturers in the health foods, nutraceuticals, and dietary supplement markets. Cyanotech also provides contract extraction services.

What do analysts say about CYAN stock?

AI analysis is pending for CYAN, so a comprehensive analyst consensus is not currently available. However, key valuation metrics such as the negative P/E ratio of -1.35 and the negative profit margin of -7.1% suggest that the company faces profitability challenges. The gross margin of 32.1% indicates potential for improvement. Growth considerations include expanding distribution channels, increasing consumer awareness, and developing new products. Investors should conduct thorough due diligence and consider the risks associated with OTC-traded companies before making any investment decisions.

What are the main risks for CYAN?

Cyanotech faces several risks, including increased competition from larger nutraceutical companies with greater resources, potential changes in regulatory requirements for dietary supplements, and fluctuations in raw material prices, which could impact profitability. Negative publicity regarding the safety or efficacy of astaxanthin or spirulina could also harm the company's reputation and sales. Additionally, the company's negative profit margin and limited financial resources pose ongoing challenges to its long-term sustainability. As an OTC-traded company, CYAN is subject to less stringent regulatory oversight, which introduces additional risks for investors.